人们期待已久的抗结肠直肠癌新药Erbitux终于顺利登陆美国,开发商百时美施贵宝公司似乎并不急于争抢地盘,而是继续专注如何获得更多的实际临床数据。Erbitux上市的第一个季度由于没有广告的介入宣传活动显得颇低调,但百时美施贵宝显然对该品的首期表现甚感满意并预计该品的销售 People long-awaited anti-colorectal cancer drug Erbitux finally successfully landed in the United States, the developer Bristol-Myers Squibb does not seem eager to compete for sites, but continue to focus on how to get more actual clinical data. In the first quarter of Erbitux’s IPO, Bristol-Myers Squibb was clearly satisfied with the initial performance of the product due to the low profile of advertising-free interventions and expected sales of the product